董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James J. Antal | 男 | Director | 64 | 9.74万美元 | 未持股 | 2015-04-14 |
| Eric A. Rose | 男 | Chairman of the Board and Chief Executive Officer | 64 | 141.31万美元 | 未持股 | 2015-04-14 |
| Michael J. Bayer | 男 | Director | 67 | 7.17万美元 | 未持股 | 2015-04-14 |
| Joseph W. Marshall, III | 男 | Director | 62 | 7.30万美元 | 未持股 | 2015-04-14 |
| Paul G. Savas | 男 | Director | 52 | 9.22万美元 | 未持股 | 2015-04-14 |
| Bruce Slovin | 男 | Director | 79 | 8.04万美元 | 未持股 | 2015-04-14 |
| Andrew L. Stern | 男 | Director | 64 | 7.14万美元 | 未持股 | 2015-04-14 |
| Thomas E. Constance | 男 | Director | 78 | 7.14万美元 | 未持股 | 2015-04-14 |
| Jeffrey B. Kindler | 男 | Director | 59 | 7.09万美元 | 未持股 | 2015-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric A. Rose | 男 | Chairman of the Board and Chief Executive Officer | 64 | 141.31万美元 | 未持股 | 2015-04-14 |
| Dennis E. Hruby | 男 | Vice President and Chief Scientific Officer | 63 | 78.17万美元 | 未持股 | 2015-04-14 |
| Daniel J. Luckshire | 男 | Executive Vice President, Chief Financial Officer and Secretary | 44 | 77.21万美元 | 未持股 | 2015-04-14 |
| William J. Haynes | 男 | Executive Vice President and General Counsel | 57 | 72.87万美元 | 未持股 | 2015-04-14 |
董事简历
中英对照 | 中文 | 英文- James J. Antal
-
James J. Antal在2006年7月成为我们董事会的成员。1996年至2001年担任益百利集团有限公司财务总监，2001至2002年担任首席投资总监。益百利是消费者和企业信用信息、直接营销信息服务以及集成的客户关系管理流程的全球领先供应商。从1997年到2002年，他还担任First American房地产解决方案（First American金融公司的Experian合资企业）的董事会董事。从2002年开始担任Plexus Vaccine公司（一家生物技术公司）的董事会顾问，直到它在2004年被SIGA技术收购。2004年12月，他加入SIGA的董事会，现担任其审计及企业管治委员会成员。 2004年5月至2005年8月受聘担任黑山黄金咖啡有限公司的首席财务顾问。2005年7月至2009年8月以兼职形式出任Pathway Data 公司（一家私人控股公司，主要从事消费信贷的通知和身份盗窃援助服务）的财务总监。1973年获得美国俄亥俄州立大学的工商管理会计专业理学士学位。在1975年成为一名俄亥俄州的注册会计师。
James J. Antal,has served as one our directors since July 2006. Mr. Antal served as Chief Financial Officer of Experian Group Ltd. from 1996 to 2001 and as Chief Investment Officer from 2001 to 2002. Experian is a leading global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. From 1997 to 2002 he also served on the board of directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Starting in 2002 Mr. Antal served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004 he joined the SIGA board of directors, and also currently serves on its audit and nominating and governance committees. From May 2004 to August 2005 he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. From July 2005 to August 2009 he served on a part-time basis as Chief Financial Officer of Pathway Data Inc., a privately-held company engaged in consumer credit notification and identity theft assistance services. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from the Ohio State University in 1973. He became a Certified Public Accountant Ohio in 1975. Mr. Antal’s experience in accounting and finance, particularly with respect to biotechnology companies and public reporting companies, make him an important asset to our board and a qualified Audit Committee Chairman. - James J. Antal在2006年7月成为我们董事会的成员。1996年至2001年担任益百利集团有限公司财务总监，2001至2002年担任首席投资总监。益百利是消费者和企业信用信息、直接营销信息服务以及集成的客户关系管理流程的全球领先供应商。从1997年到2002年，他还担任First American房地产解决方案（First American金融公司的Experian合资企业）的董事会董事。从2002年开始担任Plexus Vaccine公司（一家生物技术公司）的董事会顾问，直到它在2004年被SIGA技术收购。2004年12月，他加入SIGA的董事会，现担任其审计及企业管治委员会成员。 2004年5月至2005年8月受聘担任黑山黄金咖啡有限公司的首席财务顾问。2005年7月至2009年8月以兼职形式出任Pathway Data 公司（一家私人控股公司，主要从事消费信贷的通知和身份盗窃援助服务）的财务总监。1973年获得美国俄亥俄州立大学的工商管理会计专业理学士学位。在1975年成为一名俄亥俄州的注册会计师。
- James J. Antal,has served as one our directors since July 2006. Mr. Antal served as Chief Financial Officer of Experian Group Ltd. from 1996 to 2001 and as Chief Investment Officer from 2001 to 2002. Experian is a leading global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. From 1997 to 2002 he also served on the board of directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Starting in 2002 Mr. Antal served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004 he joined the SIGA board of directors, and also currently serves on its audit and nominating and governance committees. From May 2004 to August 2005 he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. From July 2005 to August 2009 he served on a part-time basis as Chief Financial Officer of Pathway Data Inc., a privately-held company engaged in consumer credit notification and identity theft assistance services. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from the Ohio State University in 1973. He became a Certified Public Accountant Ohio in 1975. Mr. Antal’s experience in accounting and finance, particularly with respect to biotechnology companies and public reporting companies, make him an important asset to our board and a qualified Audit Committee Chairman.
- Eric A. Rose
-
Eric A. Rose， 他是医学博士。2007年1月25日，他被选为董事会主席，2007年3月1日成为公司首席执行官。2001年4月19日起，他担任SIGA的董事，2001年4月至6月，担任SIGA的临时首席执行官；2008至2012年，担任西奈山医学院（Mount Sinai School of Medicine）医疗证据与政策部门主席，目前是共同主席和教授；1994至2007年，担任纽约长老会医院哥伦比亚长老会中心外科部门主席和首席外科医生。他是上市公司Abiomed, Inc., Nephros, Inc.和Keryx Biopharmaceuticals, Inc.的前董事、私营公司PharmaCore, Inc., TransTech Pharma, Inc.和Nexell Therapeutics Inc的前董事。他毕业于哥伦比亚学院（Columbia College）和哥伦比亚大学内科与外科学院（Columbia University College of Physicians & Surgeons）。除了在SIGA的职位以外，他还担任MacAndrews & Forbes Holdings Inc.的生命科学执行副总裁，该公司是SIGA股东的附属公司。2013年4月，他成为Mesoblast Inc.的董事和科学技术委员会主席。
Eric A. Rose served as Chairman of SIGA Technologies, Inc. "SIGA", a developer of antiviral drugs directed at potential agents of bioterror, from 2013 until June 2021. SIGA successfully developed a cure for smallpox, which is now in the strategic national stockpile of the United States government. The company has received more than $600 million in contract revenue and research support from the United States Biomedical Advanced Research and Development Authority. The company filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer and Chairman of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2013 where he now serves as professor. From 1994 to 2007 he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia's Department of Surgery over 25 years while investigating, managing and developing complex medical technologies. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984 and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University. - Eric A. Rose， 他是医学博士。2007年1月25日，他被选为董事会主席，2007年3月1日成为公司首席执行官。2001年4月19日起，他担任SIGA的董事，2001年4月至6月，担任SIGA的临时首席执行官；2008至2012年，担任西奈山医学院（Mount Sinai School of Medicine）医疗证据与政策部门主席，目前是共同主席和教授；1994至2007年，担任纽约长老会医院哥伦比亚长老会中心外科部门主席和首席外科医生。他是上市公司Abiomed, Inc., Nephros, Inc.和Keryx Biopharmaceuticals, Inc.的前董事、私营公司PharmaCore, Inc., TransTech Pharma, Inc.和Nexell Therapeutics Inc的前董事。他毕业于哥伦比亚学院（Columbia College）和哥伦比亚大学内科与外科学院（Columbia University College of Physicians & Surgeons）。除了在SIGA的职位以外，他还担任MacAndrews & Forbes Holdings Inc.的生命科学执行副总裁，该公司是SIGA股东的附属公司。2013年4月，他成为Mesoblast Inc.的董事和科学技术委员会主席。
- Eric A. Rose served as Chairman of SIGA Technologies, Inc. "SIGA", a developer of antiviral drugs directed at potential agents of bioterror, from 2013 until June 2021. SIGA successfully developed a cure for smallpox, which is now in the strategic national stockpile of the United States government. The company has received more than $600 million in contract revenue and research support from the United States Biomedical Advanced Research and Development Authority. The company filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer and Chairman of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2013 where he now serves as professor. From 1994 to 2007 he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia's Department of Surgery over 25 years while investigating, managing and developing complex medical technologies. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984 and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University.
- Michael J. Bayer
-
Michael J. Bayer，2008年10月起，他担任SIGA的董事；1992年起，担任能源与国家安全私人顾问。他是能源与国家安全咨询公司Dumbarton Strategies LLC的总裁和首席执行官。他是美国国防部商业董事会的前主席，并且是桑迪亚国家实验室（Sandia National Laboratory）核武器对外咨询小组、美国国防部（U.S. Department of Defense）科学董事会成员以及海军作战执行小组首脑。他是Willbros Group, Inc.， 戴恩国际（Dyncorp International）， Stratos Global Corporation， 杜拉泰克公司（Duratek, Inc.）和Athena Inc.的前董事。他给董事会带来了多年的国防业经验，为我公司在高度相关产业提供了意见，为政府关系提供指导，尤其是国防部和其他政府机构。
Michael J. Bayer has served as a director of SIGA since October 2008. Mr. Bayer has been a private consultant in the energy and national security sectors since 1992. Mr. Bayer is the President and Chief Executive Officer of Dumbarton Strategies LLC, an energy and national security consulting firm. He is the former Chairman of the U.S. Department of Defense's Business Board and serves as a member of the Sandia National Laboratory's Nuclear Weapons External Advisory Panel, the U.S. Department of Defense's Science Board and the Chief of Naval Operations' Executive Panel. Mr. Bayer is a former director of Willbros Group, Inc., Dyncorp International, Stratos Global Corporation, Duratek, Inc. and Athena Inc. - Michael J. Bayer，2008年10月起，他担任SIGA的董事；1992年起，担任能源与国家安全私人顾问。他是能源与国家安全咨询公司Dumbarton Strategies LLC的总裁和首席执行官。他是美国国防部商业董事会的前主席，并且是桑迪亚国家实验室（Sandia National Laboratory）核武器对外咨询小组、美国国防部（U.S. Department of Defense）科学董事会成员以及海军作战执行小组首脑。他是Willbros Group, Inc.， 戴恩国际（Dyncorp International）， Stratos Global Corporation， 杜拉泰克公司（Duratek, Inc.）和Athena Inc.的前董事。他给董事会带来了多年的国防业经验，为我公司在高度相关产业提供了意见，为政府关系提供指导，尤其是国防部和其他政府机构。
- Michael J. Bayer has served as a director of SIGA since October 2008. Mr. Bayer has been a private consultant in the energy and national security sectors since 1992. Mr. Bayer is the President and Chief Executive Officer of Dumbarton Strategies LLC, an energy and national security consulting firm. He is the former Chairman of the U.S. Department of Defense's Business Board and serves as a member of the Sandia National Laboratory's Nuclear Weapons External Advisory Panel, the U.S. Department of Defense's Science Board and the Chief of Naval Operations' Executive Panel. Mr. Bayer is a former director of Willbros Group, Inc., Dyncorp International, Stratos Global Corporation, Duratek, Inc. and Athena Inc.
- Joseph W. Marshall, III
-
Joseph W. Marshall, III，自2013年10月起担任董事会成员。2010年2月以来，他还担任律师事务所Stevens & Lee的副主席，以及Griffin Holdings， LLC的副主席。除了许多其他董事会成员，包括美国东部地区医疗中心的癌症治疗中心和特拉华第一银行，他还担任SIGA Technologies， Inc.的董事会成员。纳斯达克自2009年以来。从2001年到2008年，他担任Temple University Health System（宾夕法尼亚州最大的医疗保健组织之一）的董事长兼首席执行官。从2003年到2008年，他担任Health Partners（医疗补助/医疗保险健康维护组织，在大费城运营）的董事。他还曾任职于宾夕法尼亚博彩控制委员会、宾夕法尼亚伦理委员会和医疗补助委员会，该委员会由国会创建，并由美国卫生与人类服务部部长Michael O. Leavitt建立。此外，他是Temple大学和Salus大学的董事会成员。
Joseph W. Marshall, III has served as a member of Board of Directors since October 2013. Mr. Marshall has also served as the Vice Chairman of the law firm Stevens & Lee, PC and Vice Chairman of Griffin Holdings, LLC since February 2010. In addition to a number of other boards, including the Cancer Treatment Centers of American-Eastern Regional Medical Center and First Bank of Delaware, Mr. Marshall has served on the Board of Directors of SIGA Technologies, Inc. NASDAQ since 2009. From 2001 to 2008 Mr. Marshall served as the Chairman and CEO of Temple University Health System, one of the largest health care organizations in Pennsylvania. Mr. Marshall served as director of Health Partners, a provider-owned Medicaid/Medicare Health Maintenance Organization operating in Greater Philadelphia, from 2003 to 2008. Mr. Marshall also previously served on the Pennsylvania Gaming Control Board, Pennsylvania Ethics Commission and the Medicaid Commission created by Congress and established by the Honorable Michael O. Leavitt, Secretary of the U.S. Department of Health & Human Services. In addition, Mr. Marshall is a member of the Board of Trustees of Temple University and Salus University. - Joseph W. Marshall, III，自2013年10月起担任董事会成员。2010年2月以来，他还担任律师事务所Stevens & Lee的副主席，以及Griffin Holdings， LLC的副主席。除了许多其他董事会成员，包括美国东部地区医疗中心的癌症治疗中心和特拉华第一银行，他还担任SIGA Technologies， Inc.的董事会成员。纳斯达克自2009年以来。从2001年到2008年，他担任Temple University Health System（宾夕法尼亚州最大的医疗保健组织之一）的董事长兼首席执行官。从2003年到2008年，他担任Health Partners（医疗补助/医疗保险健康维护组织，在大费城运营）的董事。他还曾任职于宾夕法尼亚博彩控制委员会、宾夕法尼亚伦理委员会和医疗补助委员会，该委员会由国会创建，并由美国卫生与人类服务部部长Michael O. Leavitt建立。此外，他是Temple大学和Salus大学的董事会成员。
- Joseph W. Marshall, III has served as a member of Board of Directors since October 2013. Mr. Marshall has also served as the Vice Chairman of the law firm Stevens & Lee, PC and Vice Chairman of Griffin Holdings, LLC since February 2010. In addition to a number of other boards, including the Cancer Treatment Centers of American-Eastern Regional Medical Center and First Bank of Delaware, Mr. Marshall has served on the Board of Directors of SIGA Technologies, Inc. NASDAQ since 2009. From 2001 to 2008 Mr. Marshall served as the Chairman and CEO of Temple University Health System, one of the largest health care organizations in Pennsylvania. Mr. Marshall served as director of Health Partners, a provider-owned Medicaid/Medicare Health Maintenance Organization operating in Greater Philadelphia, from 2003 to 2008. Mr. Marshall also previously served on the Pennsylvania Gaming Control Board, Pennsylvania Ethics Commission and the Medicaid Commission created by Congress and established by the Honorable Michael O. Leavitt, Secretary of the U.S. Department of Health & Human Services. In addition, Mr. Marshall is a member of the Board of Trustees of Temple University and Salus University.
- Paul G. Savas
-
Paul G. Savas， 2004年1月起，他担任SIGA的董事。他是MacAndrews Holdings的执行副总裁和首席财务官。1994年，他加入MacAndrews Holdings担任公司财政董事，2007年成为首席财务官。他还担任M&F Worldwide Corp.的执行副总裁和首席财务官和Harland Clarke Holding Corp.和TransTech Pharma, Inc.的董事。过去6年内，他担任REV Holdings LLC.的董事成员。他给董事会提供了关于我公司的战略、运营和财政导向的有价值的的商业、领导和管理见解。
Paul G. Savas has served on our Board of Directors since April 2015. Mr. Savas is Executive Vice President and Chief Financial Officer at MacAndrews. He joined MacAndrews in 1994 as Director of Corporate Finance, served in various positions of increasing responsibility and became Chief Financial Officer in 2007. He also serves as a director of Harland Clarke Holding Corp., SIGA Technologies, Inc., and Revlon, Inc., and served as a member of the Board of Directors of vTvx Holdings I LLC and vTvx Holdings II LLC, our predecessors, from 2007 through 015. He holds a bachelor's degree in Accounting from Rutgers University and an M.B.A. from Fordham University. Mr. Savas provides our Board of Directors valuable business, leadership and management insights with respect to our strategic, operational and financial direction. - Paul G. Savas， 2004年1月起，他担任SIGA的董事。他是MacAndrews Holdings的执行副总裁和首席财务官。1994年，他加入MacAndrews Holdings担任公司财政董事，2007年成为首席财务官。他还担任M&F Worldwide Corp.的执行副总裁和首席财务官和Harland Clarke Holding Corp.和TransTech Pharma, Inc.的董事。过去6年内，他担任REV Holdings LLC.的董事成员。他给董事会提供了关于我公司的战略、运营和财政导向的有价值的的商业、领导和管理见解。
- Paul G. Savas has served on our Board of Directors since April 2015. Mr. Savas is Executive Vice President and Chief Financial Officer at MacAndrews. He joined MacAndrews in 1994 as Director of Corporate Finance, served in various positions of increasing responsibility and became Chief Financial Officer in 2007. He also serves as a director of Harland Clarke Holding Corp., SIGA Technologies, Inc., and Revlon, Inc., and served as a member of the Board of Directors of vTvx Holdings I LLC and vTvx Holdings II LLC, our predecessors, from 2007 through 015. He holds a bachelor's degree in Accounting from Rutgers University and an M.B.A. from Fordham University. Mr. Savas provides our Board of Directors valuable business, leadership and management insights with respect to our strategic, operational and financial direction.
- Bruce Slovin
-
2008年10月以来，Bruce Slovin 一直担任SIGA的董事。他在1 Eleven Associates, LLC（私人投资公司）担任主席有超过5年的时间。从1980年到2000年，他是MacAndrews Holdings及其几个子公司的执行官。
Bruce Slovin,President at 1 Eleven Associates, LLC, a private investment firm, since 1997. Mr. Slovin is also Chairman of MWest Holdings, LLC, a diversified commercial and residential real estate firm since 1991. He serves as director of SIGA Technologies, Inc. NASDAQ, a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens. Mr. Slovin's experience in various operating and financial positions as well as his valuable leadership role in creating and presiding over various not-for-profit organizations qualify him to serve on the Board. - 2008年10月以来，Bruce Slovin 一直担任SIGA的董事。他在1 Eleven Associates, LLC（私人投资公司）担任主席有超过5年的时间。从1980年到2000年，他是MacAndrews Holdings及其几个子公司的执行官。
- Bruce Slovin,President at 1 Eleven Associates, LLC, a private investment firm, since 1997. Mr. Slovin is also Chairman of MWest Holdings, LLC, a diversified commercial and residential real estate firm since 1991. He serves as director of SIGA Technologies, Inc. NASDAQ, a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens. Mr. Slovin's experience in various operating and financial positions as well as his valuable leadership role in creating and presiding over various not-for-profit organizations qualify him to serve on the Board.
- Andrew L. Stern
-
Andrew L. Stern自2010年6月以来一直担任SIGA的董事。Stern先生曾是美国和加拿大第二大工会--国际服务雇员工会（SEIU）的主席，并于1996年当选为该职务。Stern先生目前被任命为康奈尔大学工业和劳动关系学院的Alice B. Grant 驻校劳工领袖。他是布罗德基金会、开放社会研究所、经济政策研究所的董事会成员，阿斯彭研究所的终身受托人，凯泽医疗合作组织和SEIU全国行业养老金的主席。
Andrew L. Stern has served as a director of SIGA since June 2010. Mr. Stern was formerly the president of Service Employees International Union SEIU, the second largest union in the United States and Canada and was elected to that role in 1996. Mr. Stern currently holds an appointment as the Alice B. Grant Labor Leader in Residence at the Cornell University School of Industrial and Labor Relations. He is a board member of the Broad Foundation, the Open Society Institute, the Economic Policy Institute, a lifetime Trustee of the Aspen Institute, the President of the Kaiser Permanente Partnership and SEIU's National Industry Pension. - Andrew L. Stern自2010年6月以来一直担任SIGA的董事。Stern先生曾是美国和加拿大第二大工会--国际服务雇员工会（SEIU）的主席，并于1996年当选为该职务。Stern先生目前被任命为康奈尔大学工业和劳动关系学院的Alice B. Grant 驻校劳工领袖。他是布罗德基金会、开放社会研究所、经济政策研究所的董事会成员，阿斯彭研究所的终身受托人，凯泽医疗合作组织和SEIU全国行业养老金的主席。
- Andrew L. Stern has served as a director of SIGA since June 2010. Mr. Stern was formerly the president of Service Employees International Union SEIU, the second largest union in the United States and Canada and was elected to that role in 1996. Mr. Stern currently holds an appointment as the Alice B. Grant Labor Leader in Residence at the Cornell University School of Industrial and Labor Relations. He is a board member of the Broad Foundation, the Open Society Institute, the Economic Policy Institute, a lifetime Trustee of the Aspen Institute, the President of the Kaiser Permanente Partnership and SEIU's National Industry Pension.
- Thomas E. Constance
-
Thomas E. Constance，2010年10月1日起，担任本公司董事；2010年3月15日起，担任本银行董事。他现为 Kramer Levin Naftalis & Frankel LLP的联席董事长；1994年起，担任其合伙人，这是位于纽约市的律师事务所，本公司依然保留该公司以提供某些法律服务，其中包括涉及发行工作的代理事务。1973-1994，他任职于律师事务所Shea & Gould。他目前是M.D. Sass Foundation、St. Vincent's Services的受托人。他从2001年起，担任SIGA Technologies的董事。他在New York University获得学士学位，在St. John's University School of Law获得法律学士学位。
Thomas E. Constance has served as a director of the Company since October 1 2010 and as a director of the Bank since March 15 2010. Mr. Constance is Co-Chairman, and since 1994 a partner, of Kramer Levin Naftalis & Frankel LLP, a law firm based in New York City which the Company has retained to provide certain legal services. From 1973 to 1994 Mr. Constance was with the law firm of Shea & Gould. Mr. Constance serves as a Trustee of the M.D. Sass Foundation and St. Vincent’s Services. He has served as a director of SIGA Technologies, Inc. since 2001. Mr. Constance received a Bachelor of Science degree from New York University and a Bachelor of Law degree from St. John’s University School of Law. - Thomas E. Constance，2010年10月1日起，担任本公司董事；2010年3月15日起，担任本银行董事。他现为 Kramer Levin Naftalis & Frankel LLP的联席董事长；1994年起，担任其合伙人，这是位于纽约市的律师事务所，本公司依然保留该公司以提供某些法律服务，其中包括涉及发行工作的代理事务。1973-1994，他任职于律师事务所Shea & Gould。他目前是M.D. Sass Foundation、St. Vincent's Services的受托人。他从2001年起，担任SIGA Technologies的董事。他在New York University获得学士学位，在St. John's University School of Law获得法律学士学位。
- Thomas E. Constance has served as a director of the Company since October 1 2010 and as a director of the Bank since March 15 2010. Mr. Constance is Co-Chairman, and since 1994 a partner, of Kramer Levin Naftalis & Frankel LLP, a law firm based in New York City which the Company has retained to provide certain legal services. From 1973 to 1994 Mr. Constance was with the law firm of Shea & Gould. Mr. Constance serves as a Trustee of the M.D. Sass Foundation and St. Vincent’s Services. He has served as a director of SIGA Technologies, Inc. since 2001. Mr. Constance received a Bachelor of Science degree from New York University and a Bachelor of Law degree from St. John’s University School of Law.
- Jeffrey B. Kindler
-
Jeffrey B. Kindler，一些私人保健服务公司董事、顾问及投资者。他现任一家私营制药公司Centrexion公司的首席执行官。除了Chipotle，他还在两家其他上市公司的董事会及几个非营利组织工作过；两家上市公司是Intrexon公司（纽约证券交易所：XON）和Siga科技公司（纳克达斯全球交易市场：SIGA）。他于2010年12月从辉瑞制药公司退休，曾于此担任董事长兼首席执行官。他于2002年进入辉瑞担任高级副总裁兼总顾问，且被指派的职务职责不断提高，直到2006年被任命为首席执行官。在进入辉瑞之前，他是麦当劳公司的行政人员；且在2001年期间，他接手负责该公司的合伙品牌集团（Chipotle也包含在内）。
Jeffrey B. Kindler,2020 - Present Venture Partner, Artis Ventures, venture fund focused on life-sciences companies.2020 - Present Senior Advisor, Blackstone Group, the world's largest alternative asset manager.2013 - Present CEO, Centrexion Corporation, a biopharmaceutical company. - Jeffrey B. Kindler，一些私人保健服务公司董事、顾问及投资者。他现任一家私营制药公司Centrexion公司的首席执行官。除了Chipotle，他还在两家其他上市公司的董事会及几个非营利组织工作过；两家上市公司是Intrexon公司（纽约证券交易所：XON）和Siga科技公司（纳克达斯全球交易市场：SIGA）。他于2010年12月从辉瑞制药公司退休，曾于此担任董事长兼首席执行官。他于2002年进入辉瑞担任高级副总裁兼总顾问，且被指派的职务职责不断提高，直到2006年被任命为首席执行官。在进入辉瑞之前，他是麦当劳公司的行政人员；且在2001年期间，他接手负责该公司的合伙品牌集团（Chipotle也包含在内）。
- Jeffrey B. Kindler,2020 - Present Venture Partner, Artis Ventures, venture fund focused on life-sciences companies.2020 - Present Senior Advisor, Blackstone Group, the world's largest alternative asset manager.2013 - Present CEO, Centrexion Corporation, a biopharmaceutical company.
高管简历
中英对照 | 中文 | 英文- Eric A. Rose
Eric A. Rose， 他是医学博士。2007年1月25日，他被选为董事会主席，2007年3月1日成为公司首席执行官。2001年4月19日起，他担任SIGA的董事，2001年4月至6月，担任SIGA的临时首席执行官；2008至2012年，担任西奈山医学院（Mount Sinai School of Medicine）医疗证据与政策部门主席，目前是共同主席和教授；1994至2007年，担任纽约长老会医院哥伦比亚长老会中心外科部门主席和首席外科医生。他是上市公司Abiomed, Inc., Nephros, Inc.和Keryx Biopharmaceuticals, Inc.的前董事、私营公司PharmaCore, Inc., TransTech Pharma, Inc.和Nexell Therapeutics Inc的前董事。他毕业于哥伦比亚学院（Columbia College）和哥伦比亚大学内科与外科学院（Columbia University College of Physicians & Surgeons）。除了在SIGA的职位以外，他还担任MacAndrews & Forbes Holdings Inc.的生命科学执行副总裁，该公司是SIGA股东的附属公司。2013年4月，他成为Mesoblast Inc.的董事和科学技术委员会主席。
Eric A. Rose served as Chairman of SIGA Technologies, Inc. "SIGA", a developer of antiviral drugs directed at potential agents of bioterror, from 2013 until June 2021. SIGA successfully developed a cure for smallpox, which is now in the strategic national stockpile of the United States government. The company has received more than $600 million in contract revenue and research support from the United States Biomedical Advanced Research and Development Authority. The company filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer and Chairman of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2013 where he now serves as professor. From 1994 to 2007 he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia's Department of Surgery over 25 years while investigating, managing and developing complex medical technologies. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984 and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University.- Eric A. Rose， 他是医学博士。2007年1月25日，他被选为董事会主席，2007年3月1日成为公司首席执行官。2001年4月19日起，他担任SIGA的董事，2001年4月至6月，担任SIGA的临时首席执行官；2008至2012年，担任西奈山医学院（Mount Sinai School of Medicine）医疗证据与政策部门主席，目前是共同主席和教授；1994至2007年，担任纽约长老会医院哥伦比亚长老会中心外科部门主席和首席外科医生。他是上市公司Abiomed, Inc., Nephros, Inc.和Keryx Biopharmaceuticals, Inc.的前董事、私营公司PharmaCore, Inc., TransTech Pharma, Inc.和Nexell Therapeutics Inc的前董事。他毕业于哥伦比亚学院（Columbia College）和哥伦比亚大学内科与外科学院（Columbia University College of Physicians & Surgeons）。除了在SIGA的职位以外，他还担任MacAndrews & Forbes Holdings Inc.的生命科学执行副总裁，该公司是SIGA股东的附属公司。2013年4月，他成为Mesoblast Inc.的董事和科学技术委员会主席。
- Eric A. Rose served as Chairman of SIGA Technologies, Inc. "SIGA", a developer of antiviral drugs directed at potential agents of bioterror, from 2013 until June 2021. SIGA successfully developed a cure for smallpox, which is now in the strategic national stockpile of the United States government. The company has received more than $600 million in contract revenue and research support from the United States Biomedical Advanced Research and Development Authority. The company filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer and Chairman of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2013 where he now serves as professor. From 1994 to 2007 he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia's Department of Surgery over 25 years while investigating, managing and developing complex medical technologies. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984 and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University.
- Dennis E. Hruby
Dennis E. Hruby， 他是哲学博士。2000年6月起，他担任副总裁和首席科技官；1997年4月1日至2000年6月，担任我公司研究副总裁；1996年1月至1997年3月，担任SIGA的高级科学顾问。他是俄勒冈州立大学（Oregon State University）微生物兼职教授，1990至1993年，担任分子与细胞生物项目的董事和基因研究与生物技术中心（Center for Gene Research and Biotechnology）的助理董事。他的专长是病毒学和细胞生物研究、使用病毒和细菌携带者生产重组疫苗和抗病毒开发。他是美国病毒学协会（American Society of Virology）、美国微生物协会（American Society for Microbiology）和美国微生物学会（American Academy of Microbiology）的成员。他在科罗拉多大学医学中心（University of Colorado Medical Center）获得微生物学博士学位，在俄勒冈州立大学（Oregon State University）获得微生物学学士学位。
Dennis E. Hruby, Ph.D. has served as Vice President and Chief Scientific Officer since June 2000. From April 1 1997 through June 2000 Dr. Hruby was our Vice President of Research. From January 1996 through March 1997 Dr. Hruby served as a senior scientific advisor to SIGA. Dr. Hruby is an Adjunct Courtesy Professor of Microbiology at Oregon State University, and from 1990 to 1993 was Director of the Molecular and Cellular Biology Program and Associate Director of the Center for Gene Research and Biotechnology. Dr. Hruby specializes in virology and cell biology research, and the use of viral and bacterial vectors to produce recombinant vaccines as well as antiviral development. He is a member of the American Society of Virology, the American Society for Microbiology and a fellow of the American Academy of Microbiology. Dr. Hruby received a Ph.D. in microbiology from the University of Colorado Medical Center and a B.S. in microbiology from Oregon State University.- Dennis E. Hruby， 他是哲学博士。2000年6月起，他担任副总裁和首席科技官；1997年4月1日至2000年6月，担任我公司研究副总裁；1996年1月至1997年3月，担任SIGA的高级科学顾问。他是俄勒冈州立大学（Oregon State University）微生物兼职教授，1990至1993年，担任分子与细胞生物项目的董事和基因研究与生物技术中心（Center for Gene Research and Biotechnology）的助理董事。他的专长是病毒学和细胞生物研究、使用病毒和细菌携带者生产重组疫苗和抗病毒开发。他是美国病毒学协会（American Society of Virology）、美国微生物协会（American Society for Microbiology）和美国微生物学会（American Academy of Microbiology）的成员。他在科罗拉多大学医学中心（University of Colorado Medical Center）获得微生物学博士学位，在俄勒冈州立大学（Oregon State University）获得微生物学学士学位。
- Dennis E. Hruby, Ph.D. has served as Vice President and Chief Scientific Officer since June 2000. From April 1 1997 through June 2000 Dr. Hruby was our Vice President of Research. From January 1996 through March 1997 Dr. Hruby served as a senior scientific advisor to SIGA. Dr. Hruby is an Adjunct Courtesy Professor of Microbiology at Oregon State University, and from 1990 to 1993 was Director of the Molecular and Cellular Biology Program and Associate Director of the Center for Gene Research and Biotechnology. Dr. Hruby specializes in virology and cell biology research, and the use of viral and bacterial vectors to produce recombinant vaccines as well as antiviral development. He is a member of the American Society of Virology, the American Society for Microbiology and a fellow of the American Academy of Microbiology. Dr. Hruby received a Ph.D. in microbiology from the University of Colorado Medical Center and a B.S. in microbiology from Oregon State University.
- Daniel J. Luckshire
Daniel J. Luckshire，2011年2月起，他担任执行副总裁和首席财务官。加入SIGA之前，他担任专业细分市场领导公司的战略顾问和私人投资者。1998至2008年，他担任Merrill Lynch & Co.的投资银行家，并担任多职。加入Merrill Lynch之前，他担任将USI Insurance Services打造成全国保险代理机构的管理团队的成员，并担任普华永道（Price Waterhouse LLP）的注册会计师。他在宾夕法尼亚大学沃顿学院（The Wharton School of the University of Pennsylvania）获得金融和战略管理工商管理学硕士学位，在维拉诺瓦大学（Villanova University）获得理学士学位。
Daniel J. Luckshire has served as Executive Vice President and Chief Financial Officer since February 2011. Prior to joining SIGA, Mr. Luckshire was a strategic advisor and private investor for a broad range of companies within specialized market segments. Between 1998 and 2008 Mr. Luckshire was an investment banker at Merrill Lynch & Co., where he held various positions of increasing responsibility. Prior to his employment with Merrill Lynch, Mr. Luckshire was a member of the management team that built USI Insurance Services into a national insurance brokerage and was a CPA at Price Waterhouse LLP. Mr. Luckshire has a Master of Business Administration degree in Finance and Strategic Management from The Wharton School of the University of Pennsylvania and a Bachelor of Science degree from Villanova University.- Daniel J. Luckshire，2011年2月起，他担任执行副总裁和首席财务官。加入SIGA之前，他担任专业细分市场领导公司的战略顾问和私人投资者。1998至2008年，他担任Merrill Lynch & Co.的投资银行家，并担任多职。加入Merrill Lynch之前，他担任将USI Insurance Services打造成全国保险代理机构的管理团队的成员，并担任普华永道（Price Waterhouse LLP）的注册会计师。他在宾夕法尼亚大学沃顿学院（The Wharton School of the University of Pennsylvania）获得金融和战略管理工商管理学硕士学位，在维拉诺瓦大学（Villanova University）获得理学士学位。
- Daniel J. Luckshire has served as Executive Vice President and Chief Financial Officer since February 2011. Prior to joining SIGA, Mr. Luckshire was a strategic advisor and private investor for a broad range of companies within specialized market segments. Between 1998 and 2008 Mr. Luckshire was an investment banker at Merrill Lynch & Co., where he held various positions of increasing responsibility. Prior to his employment with Merrill Lynch, Mr. Luckshire was a member of the management team that built USI Insurance Services into a national insurance brokerage and was a CPA at Price Waterhouse LLP. Mr. Luckshire has a Master of Business Administration degree in Finance and Strategic Management from The Wharton School of the University of Pennsylvania and a Bachelor of Science degree from Villanova University.
- William J. Haynes
William J. Haynes，2012年6月起，他担任执行副总裁和总顾问；他在商界和美国政府担任多个高级职位，包括2008至2012年担任雪佛龙公司（Chevron Corporation）的首席公司顾问，2001至2008年担任国防部的总顾问，1993至1996年和1999至2001年担任国家律师事务所Jenner & Block的合伙人，1996至1999年担任通用动力公司（General Dynamics Corporation）的副总裁和总顾问助理 ，1989至1993年担任陆军部的总顾问。他在哈佛法学院（Harvard Law School）获得法学博士学位，在戴维森学院（Davidson College）获得文学士学位。
William J. Haynes has served as Executive Vice President and General Counsel since June 2012. Mr. Haynes has held a number of senior positions in the private sector and the U.S. Government, including Chief Corporate Counsel at Chevron Corporation 2008 to 2012 General Counsel of the Department of Defense (2001 to 2008), partner in the national law firm Jenner & Block (1993 to 1996 and 1999 to 2001), Vice President and Associate General Counsel of General Dynamics Corporation (1996 to 1999), and General Counsel of the Department of the Army (1989 to 1993). Mr. Haynes serves as a director of the United States Supreme Court Historical Society, a director of the Greater New York Councils of the Boy Scouts of America, and a member of the Veterans’ Policy Oversight Committee of the American Legion. Mr. Haynes earned his Juris Doctor degree from Harvard Law School, and his Bachelor of Arts degree from Davidson College.- William J. Haynes，2012年6月起，他担任执行副总裁和总顾问；他在商界和美国政府担任多个高级职位，包括2008至2012年担任雪佛龙公司（Chevron Corporation）的首席公司顾问，2001至2008年担任国防部的总顾问，1993至1996年和1999至2001年担任国家律师事务所Jenner & Block的合伙人，1996至1999年担任通用动力公司（General Dynamics Corporation）的副总裁和总顾问助理 ，1989至1993年担任陆军部的总顾问。他在哈佛法学院（Harvard Law School）获得法学博士学位，在戴维森学院（Davidson College）获得文学士学位。
- William J. Haynes has served as Executive Vice President and General Counsel since June 2012. Mr. Haynes has held a number of senior positions in the private sector and the U.S. Government, including Chief Corporate Counsel at Chevron Corporation 2008 to 2012 General Counsel of the Department of Defense (2001 to 2008), partner in the national law firm Jenner & Block (1993 to 1996 and 1999 to 2001), Vice President and Associate General Counsel of General Dynamics Corporation (1996 to 1999), and General Counsel of the Department of the Army (1989 to 1993). Mr. Haynes serves as a director of the United States Supreme Court Historical Society, a director of the Greater New York Councils of the Boy Scouts of America, and a member of the Veterans’ Policy Oversight Committee of the American Legion. Mr. Haynes earned his Juris Doctor degree from Harvard Law School, and his Bachelor of Arts degree from Davidson College.